JP2016117765A5 - - Google Patents

Download PDF

Info

Publication number
JP2016117765A5
JP2016117765A5 JP2016054872A JP2016054872A JP2016117765A5 JP 2016117765 A5 JP2016117765 A5 JP 2016117765A5 JP 2016054872 A JP2016054872 A JP 2016054872A JP 2016054872 A JP2016054872 A JP 2016054872A JP 2016117765 A5 JP2016117765 A5 JP 2016117765A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
item
type
facial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016054872A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016117765A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016117765A publication Critical patent/JP2016117765A/ja
Publication of JP2016117765A5 publication Critical patent/JP2016117765A5/ja
Pending legal-status Critical Current

Links

JP2016054872A 2011-01-24 2016-03-18 ナノ粒子組成物、その製剤およびその使用 Pending JP2016117765A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161435778P 2011-01-24 2011-01-24
US61/435,778 2011-01-24

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013551271A Division JP5943258B2 (ja) 2011-01-24 2012-01-23 ナノ粒子組成物、その製剤およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017207274A Division JP6596475B2 (ja) 2011-01-24 2017-10-26 ナノ粒子組成物、その製剤およびその使用

Publications (2)

Publication Number Publication Date
JP2016117765A JP2016117765A (ja) 2016-06-30
JP2016117765A5 true JP2016117765A5 (https=) 2017-07-13

Family

ID=45554904

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2013551271A Active JP5943258B2 (ja) 2011-01-24 2012-01-23 ナノ粒子組成物、その製剤およびその使用
JP2016054872A Pending JP2016117765A (ja) 2011-01-24 2016-03-18 ナノ粒子組成物、その製剤およびその使用
JP2017207274A Active JP6596475B2 (ja) 2011-01-24 2017-10-26 ナノ粒子組成物、その製剤およびその使用
JP2019125459A Active JP7166992B2 (ja) 2011-01-24 2019-07-04 ナノ粒子組成物、その製剤およびその使用
JP2021055533A Pending JP2021105015A (ja) 2011-01-24 2021-03-29 ナノ粒子組成物、その製剤およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2013551271A Active JP5943258B2 (ja) 2011-01-24 2012-01-23 ナノ粒子組成物、その製剤およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2017207274A Active JP6596475B2 (ja) 2011-01-24 2017-10-26 ナノ粒子組成物、その製剤およびその使用
JP2019125459A Active JP7166992B2 (ja) 2011-01-24 2019-07-04 ナノ粒子組成物、その製剤およびその使用
JP2021055533A Pending JP2021105015A (ja) 2011-01-24 2021-03-29 ナノ粒子組成物、その製剤およびその使用

Country Status (10)

Country Link
US (4) US20120328701A1 (https=)
EP (2) EP3689331A1 (https=)
JP (5) JP5943258B2 (https=)
KR (5) KR20140005998A (https=)
CN (2) CN103596559A (https=)
AU (4) AU2012209274A1 (https=)
BR (1) BR112013018920A2 (https=)
IL (3) IL313839A (https=)
SG (2) SG10201804552WA (https=)
WO (1) WO2012103038A2 (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) * 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9486408B2 (en) * 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
SG10201607909WA (en) 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2008151022A2 (en) 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
MY151973A (en) 2007-08-17 2014-07-31 Novartis Ag Cyclic depsipeptides
EP2667854B1 (en) * 2011-01-24 2019-01-16 Anterios, Inc. Nanoparticle compositions
US8680054B2 (en) 2011-04-20 2014-03-25 Novartis Ag Suspension type topical formulations comprising cyclic depsipeptide
US8614289B2 (en) 2011-04-20 2013-12-24 Novartis Ag Processes for the manufacture of macrocyclic depsipeptides and new intermediates
US20140051637A1 (en) * 2011-04-28 2014-02-20 National University Corporation Nagoya University Brain-targeting functional nucleic acid and use thereof
US9849512B2 (en) 2011-07-01 2017-12-26 Attostat, Inc. Method and apparatus for production of uniformly sized nanoparticles
US10016473B2 (en) 2012-08-17 2018-07-10 Howard University Method, apparatus, and kit for the pulsing treatment of neurodegenerative diseases and impairments
US9012490B2 (en) 2012-08-17 2015-04-21 Howard University Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia
US9101652B2 (en) 2012-08-17 2015-08-11 Howard University Method, apparatus and kit for the treatment of neurodegenerative diseases and impairments
US8987413B2 (en) 2012-10-09 2015-03-24 Novartis Ag Aldehyde acetal based processes for the manufacture of macrocyclic depsipeptides and new intermediates
US9067978B2 (en) 2012-10-09 2015-06-30 Novartis Ag Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates
WO2014117070A1 (en) * 2013-01-25 2014-07-31 Nwulia Evaristus A Curcumin analogs and methods of inhibiting hiv-1
KR102092435B1 (ko) 2013-03-08 2020-03-24 예일 유니버시티 피부색소침착 감소용 조성물 및 방법
US9474720B2 (en) 2013-11-04 2016-10-25 BioPharmX, Inc. Dosage form comprising an active ingredient and a plurality of solid porous microcarriers
EP4241771A3 (en) * 2013-11-08 2023-11-22 Antivirus Therapeutics Methods and compositions for treating sepsis
EP3084445B1 (en) 2013-12-11 2020-10-28 University of Massachusetts Compositions and methods for treating disease using salmonella t3ss effector protein (sipa)
KR101478520B1 (ko) * 2014-01-24 2015-01-02 동신대학교산학협력단 피부 안전성이 향상된 캡사이신-펩타이드 및 이를 이용한 피부 외용제 조성물
AU2015252947B2 (en) * 2014-05-01 2020-07-09 Anterios, Inc. Demonstrable efficacy across or within patient populations
MX2017003903A (es) * 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
MX2017012062A (es) 2015-03-23 2018-06-18 Biopharmx Inc Composicion farmaceutica de tetraciclina para uso dermatologico.
WO2016161348A1 (en) 2015-04-01 2016-10-06 Attostat, Inc. Nanoparticle compositions and methods for treating or preventing tissue infections and diseases
WO2016168346A1 (en) * 2015-04-13 2016-10-20 Attostat, Inc. Anti-corrosion nanoparticle compositions
US11473202B2 (en) 2015-04-13 2022-10-18 Attostat, Inc. Anti-corrosion nanoparticle compositions
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
ES2596720B1 (es) * 2015-07-10 2018-01-29 Juvilis Cosmetics S.L. Composiciones para uso tópico
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
WO2018236876A2 (en) * 2017-06-19 2018-12-27 Washington University Nanoemulsion and methods of use thereof
PL3431072T3 (pl) * 2017-07-17 2020-05-18 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Emulsja olej-w-wodzie
US11306111B2 (en) 2017-07-31 2022-04-19 January Therapeutics, Inc. Organophosphate derivatives
US11646453B2 (en) 2017-11-28 2023-05-09 Attostat, Inc. Nanoparticle compositions and methods for enhancing lead-acid batteries
US11018376B2 (en) 2017-11-28 2021-05-25 Attostat, Inc. Nanoparticle compositions and methods for enhancing lead-acid batteries
WO2019113475A1 (en) * 2017-12-07 2019-06-13 Dermavant Sciences GmbH Topical ointment formulations and their use in treating skin conditions
GB201721840D0 (en) * 2017-12-22 2018-02-07 Waterford Institute Of Tech Microemulsion for opthalmic drug delivery
BR112020017645A2 (pt) 2018-03-02 2020-12-29 Elicio Therapeutics Inc. Compostos que incluem uma sequência kras mutante e um lipídio e usos dos mesmos
DK3758712T3 (da) * 2018-03-02 2025-08-04 Elicio Therapeutics Inc Cpg-amfifiler og anvendelser deraf
US20210007999A1 (en) * 2018-03-02 2021-01-14 January Therapeutics, Inc. Nanoparticle compositions
BR112021004542A2 (pt) 2018-09-13 2021-06-08 Eirion Therapeutics, Inc. inibidores do inibidor de ativador de plasminogênio 1 (pai-1) e usos para os mesmos
CA3112549A1 (en) 2018-09-13 2020-03-19 Eirion Therapeutics, Inc. Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors
BR112021009554A2 (pt) 2018-12-03 2021-08-17 Eirion Therapeutics, Inc. aplicação melhorada de agentes grandes
US20220273765A1 (en) * 2019-04-24 2022-09-01 Follicum Ab Topical formulation
CA3139983A1 (en) 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
US12115250B2 (en) 2019-07-12 2024-10-15 Evoq Nano, Inc. Use of nanoparticles for treating respiratory infections associated with cystic fibrosis
US11708637B2 (en) 2019-08-13 2023-07-25 The Regents Of The University Of California Methods of supporting a graphene sheet disposed on a frame support
DE102019215585B4 (de) * 2019-10-10 2022-02-17 KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság Verfahren zur prävention von strahlenschäden in humanen drüsen
US12456759B2 (en) 2021-03-30 2025-10-28 Evoq Nano, Inc. Nanoparticle-enhanced lead-acid electrode paste and improved lead-acid batteries made therefrom
US12599625B2 (en) 2021-05-13 2026-04-14 Penland Foundation Treatment of ARDS and other conditions caused by acutely elevated cytokine levels and post ARDS chronic cytokine production using inhaled anesthetics
WO2023287726A1 (en) 2021-07-12 2023-01-19 Penland Foundation Treatment of cancer using botulinum toxin and nitrous oxide
WO2023097296A1 (en) * 2021-11-24 2023-06-01 Jenivision Inc. Delivery methods for treating brain and central nervous system diseases
JP2026501730A (ja) * 2023-01-09 2026-01-16 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッド 脱毛症を治療するための局所用組成物及び方法
AU2024344613A1 (en) 2023-09-18 2026-04-23 Eirion Therapeutics, Inc. Topical compositions and uses of pai-1 inhibitors
WO2025165954A1 (en) * 2024-01-30 2025-08-07 The University Of North Carolina At Chapel Hill Lipid nanoemulsion formulations for contrast agents and methods of using the same
WO2025217590A1 (en) * 2024-04-11 2025-10-16 Envoya, Inc. Compositions and methods of making polymeric nanoparticles for delivery of therapeutic agents

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US296006A (en) 1884-04-01 John hoefleb
DE2929425A1 (de) * 1979-07-20 1981-02-12 Lothar Kling Vorrichtung fuer injektionsspritzen zur intramuskulaeren und subentanen injektion
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4908154A (en) 1981-04-17 1990-03-13 Biotechnology Development Corporation Method of forming a microemulsion
US4533254A (en) 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US6939852B2 (en) 1991-09-24 2005-09-06 Allergan, Inc. Methods and compositions for the treatment of cerebral palsy
US7384918B2 (en) 1991-09-24 2008-06-10 Allergan, Inc. Botulinum toxin for treating muscle contracture
US5613952A (en) * 1991-12-23 1997-03-25 Syringe Develpoment Partners Safety syringe
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69627963T2 (de) * 1995-06-06 2004-03-04 Pearce, L. Bruce, Cambridge Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US5965154A (en) 1998-03-17 1999-10-12 Plc Holding, L.L.C. Adhesive matrix type transdermal patch and method of manufacturing same
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6403779B1 (en) 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US20050020525A1 (en) 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
FR2805761B1 (fr) * 2000-03-02 2002-08-30 Mainelab Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
EP2390331B1 (en) 2001-09-28 2018-04-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. MicroRNA molecules
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
AU2003276131A1 (en) 2002-06-18 2003-12-31 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US20050013850A1 (en) * 2003-07-15 2005-01-20 Caers Jan K. Device to assist hyperhydrosis therapy
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US8734810B2 (en) * 2003-10-29 2014-05-27 Allergan, Inc. Botulinum toxin treatments of neurological and neuropsychiatric disorders
AU2005286640A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
BRPI0613631A8 (pt) 2005-07-18 2017-12-26 Univ Massachusetts Lowell nanoemulsão e método,
BRPI0619134B8 (pt) 2005-12-01 2021-05-25 Univ Massachusetts Lowell nanoemulsão, composição farmacêutica, composição, métodos cosméticos para o tratamento de rugas, linhas faciais e/ou linhas do pescoço, e de retardar o início das rugas, linhas faciais e/ou linhas do pescoço, e, método de fabricação de uma nanoemulsão
SG10201607909WA (en) * 2006-12-01 2016-11-29 Anterios Inc Peptide nanoparticles and uses therefor
WO2008070538A2 (en) * 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2008151022A2 (en) * 2007-05-31 2008-12-11 Anterios, Inc. Nucleic acid nanoparticles and uses therefor
MX379265B (es) * 2008-06-26 2025-03-11 Anterios Inc Aplicacion dérmica de toxina botulínica en nanoemulsiones para usarse en el tratamiento de trastornos de la piel.

Similar Documents

Publication Publication Date Title
JP2016117765A5 (https=)
JP2014510041A5 (https=)
JP2014528900A5 (https=)
JP6523843B2 (ja) ボツリヌス菌ナノエマルジョン
JP6976997B2 (ja) 注射用ボツリヌス毒素製剤
JP6596475B2 (ja) ナノ粒子組成物、その製剤およびその使用
JP6131194B2 (ja) 皮膚科学的症状を処置するためのエンプティナノ粒子組成物およびその使用
JP2022164750A5 (https=)
JP2014507420A (ja) パラベン組成物
JP2015514074A (ja) 局所化学的神経麻痺薬を使用して皺を処置する方法
BR112021009554A2 (pt) aplicação melhorada de agentes grandes
JPWO2018093465A5 (https=)
KR102614567B1 (ko) 안정성이 개선된 보툴리눔 독소를 포함하는 조성물 및 이를 포함하는 마이크로구조체
Sameera et al. BOTOX-A COMPREHENSIVE REVIEW AND ITS USES IN DENTISTRY
JP2004189639A (ja) 乳化組成物
BR112019010131B1 (pt) Composição de nanoemulsão, emplastro, kit e uso de um agente grande que tem um peso molecular de 100.000 da ou maior no condicionamento da pele e para tratar distúrbios dermatológicos
HK1200016B (zh) 肉毒杆菌纳米乳液
HK1234672A1 (en) Botulinum nanoemulsions